glp 1 and gallbladder disease Risks with GLP-1 Weight Loss Medications Gallbladder Risks with GLP-1 Medications

Over a mean follow-up period of 39.8 months, semaglutide demonstrated superiority over placebo in reducing the composite endpoint of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke among overweight or obese patients with established cardiovascular disease, but without diabetes

Qi, Z., Stephens, N

Slight digestive changes

1 Steno Diabetes Center Odense, Odense, 2 Department of Gynecology and Obstetrics, Odense University Hospital, Odense, 3 University of Southern Denmark, Odense, 4 Department of Endocrinology, Odense University Hospital, Odense, Denmark

Boolean operators (AND, OR) were used to combine search terms effectively